• Transformation Capital features SHRG as top performer in the TDSI direct-selling index
• SHRG achieved a staggering 1,070% growth rate compared to levels at end of February
• Industry as a whole has been outperforming market, with positive outlook for full year

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, was featured in a recent industry report published by investment banking and business development firm Transformation Capital (https://ibn.fm/kwVLW); the report listed SHRG as one of the fastest-growing small-cap companies in the space.

The report looks at the TDSI, or a market capitalization-weighted index of all U.S. publicly traded, direct-selling companies with valuations of more than $25 million. The index started tracking data beginning March 1, 2020, and now stands 56% above the initial end-of-February level, significantly outperforming the DJIA and S&P 500, which gained only 7% during the same period, demonstrating that the industry as a whole is growing much faster than general economy.

The investment bank and business development firm highlights Sharing Services Global as the top performer among all stocks in the index’s tracking set. In fact, SHRG has continued its impressive growth with a gain of 27% during August only, which means that for September, SHRG’s stock price stood at a massive 1,070% above its levels at the end of February.

Transformation Capital estimates that the industry will continue to perform in 2020, leveraging the momentum built since the beginning of the year to drive the industry towards a possible new record-breaking year. “From a broad perspective, we believe that the direct-selling industry, as a whole, is experiencing a renaissance within the domestic market,” said Transformation Capital CEO. “Domestic direct-selling revenues have been flat to slightly down since reaching an all-time high of more than $36 billion in 2016. It is our belief that 2020 sales will reach, and likely exceed, that record figure.”

The investment banking and business development firm see several bullish factors driving robust performances in the direct-selling industry, including the decline in short interest in industry stocks demonstrating that investors are becoming reluctant to take positions against them. As a result, the sentiment of the analysts covering this space is shifting, with a staggering 97% of them having “buy” or “hold” ratings on the stocks from the direct-selling space. Operating in a rapidly growing industry, SHRG offers compelling growth potential supported by its robust business model and strong fundamentals.

The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings LLC., the parent of its wholly owned subsidiary, Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC., the parent of its wholly owned subsidiary, Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line.

For more information, visit the company’s website at www.SHRGInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Kaival Brands’ flagship product, vaping device Bidi(TM) Stick, has rapidly taken dominant position in e-cigarette market
• E-cigarette segment set to grow to market size of $59.3 billion by 2027, CAGR of 19.6% over next seven years
• The Bidi(TM) Stick now available across thousands of retailers in United States, as far afield as Guam
• Kaival Brands recently reported blowout earnings, with quarterly sales surpassing $32 million

Kaival Brands Innovations Group (OTCQB: KAVL), which focuses on growing and incubating innovative and profitable products into mature, dominant brands, is the sole distributor of the Bidi(TM) Stick, an innovative completely-contained disposable nicotine vaping device designed to provide adult smokers with a premium vaping experience. The Bidi(TM) Stick has rapidly taken on a dominant position within the global e-cigarette market – a segment which is projected to grow to a market size of $59.3 billion by 2027, representing a CAGR of 19.6% over the next seven years. With consumers increasingly opting to switch to e-cigarettes amid growing awareness of the advantages of consuming smokeless and ashless nicotine products, brands such as Kaival Brands are well-positioned to make their presence felt in a space where innovation and compliance are essential determinants of success (https://ibn.fm/d8kEm).

Kaival Brands has established a budding reputation for growing and incubating innovative products and developing them into dominating in their respective markets– an approach which the company is now bringing to the rapidly growing vaping sector. As the exclusive distributor of the Bidi Stick, Kaival has sought to create a national distribution network, with the company’s products now stocked across thousands of retail and convenience store locations across the country.

“We are proud to announce that Bidi Sticks can now be found nationally in over 850 retail stores, like Fas Mart and Sprint Mart, owned by GPM Investments LLC in addition to over 2,200 current Circle K convenience stores, and we expect in the coming months for our distribution to expand potentially into thousands more retailers and convenience chains,” said Kaival president and CEO Niraj Patel (https://ibn.fm/Ppj4Z). “Bidi Sticks can also be purchased online for in-person delivery from any goPuff.com facility that has the ability to sell Bidi Sticks legally with proper age-verification gates within that state or municipality.”

Kaival Brands’ ambition is not limited to the United States, having recently begun exports of the Bidi Stick to foreign retailers.

“Internationally, we also recently shipped an initial order valued at approximately $166,000 to Ambros Inc., a company located in Guam that is the exclusive distributor of SC Johnson and Budweiser products to all retailers located in Guam,” Patel continued. “The Bidi(TM) Stick will be the only vaping device offered by Ambros Inc. to their customers and retailers.”

The impressive distribution network for the Bidi(TM) Stick coupled with the product’s innovative design and technological prowess have translated into strong financial results, with Kaival Brands Innovations Group recently releasing its third quarter earnings. Sales for the quarter ending July 31, 2020 totaled approximately $32.4 million, with gross profits of $4.4 million over the three-month period –with the figures being particularly noteworthy given that the company began to generate revenues less than twelve months ago. The company’s management attributed most of the gain to the Bidi Stick’s explosive sales growth.

“We had an extremely busy and fruitful third fiscal quarter,” said Patel. “We experienced a rising demand for our exclusively distributed premium product, the Bidi Stick. We have seen an increase in sales of almost 44% from the previous quarter, with our sales growth occurring mostly organically through smaller distribution channels and wholesalers. Now in the fourth fiscal quarter, we are focused on expanding our distribution into large national retailers and convenience chains.”

With the vaping industry set to enjoy a double-digit growth for the foreseeable future, Kaival Brands is well-positioned to continue benefitting from the growing popularity of its flagship product, the Bidi Stick.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• PACR has strategic licensing agreement with Phenome One, which owns Canada’s largest live genetic cannabis library
• The company’s optimized farming system distinguishes it from other cannabis operations
• Pac Roots Cannabis Corp.’s commitment to superior genetics involves careful selection of cultivation sites

With its slogan proclaiming “the Future of Genetics,” Canadian cannabis company Pac Roots Cannabis (CSE: PACR) clearly places a top priority on producing premium-quality cannabis strains and products. In fact, while some companies may strive to be the largest cannabis grower, Pac Roots Cannabis Corp. maintains that the quality of the product is paramount.

Pac Roots Cannabis Corp. achieves its goal of producing the highest-quality cannabis by relying on superior genetics, following optimized farming systems and growing in carefully selected cultivation sites. The company’s commitment to superior genetics is represented by its strategic licensing agreement with Phenome One, which owns one of Canada’s largest live genetic cannabis libraries. That library includes more than 350 cultivars that have been lab tested and rigorously field-tested over 30 years (https://pacroots.ca/genetics/).

The company’s optimized farming system also distinguishes it from other cannabis operations. These remarkable farming systems are essential in the company’s unerring quest for a quality product. Pac Roots Cannabis Corp. works closely with its selected partners to optimize cultivation through unique, proprietary methods, including the following essential aspects (https://ibn.fm/5ryoU):

• Custom-formulated nutrients
• Systematic planting of young, hardy cultivars, which provides maximum growth and resilience
• Careful weed control achieved through row compaction and mowing
• Complex irrigation systems that deliver nutrients and spring water directly to each plant site

Finally, the third essential piece of Pac Roots Cannabis Corp.’s commitment to superior genetics involves its careful selection of cultivation sites located in some of the best outdoor growing climates in Canada, including the South Okanagan Valley and the Fraser Valley Regional District.

The company’s Rock Creek Farms site, a 100-acre, premium-hemp joint venture, is nestled in the South Okanagan Valley in British Columbia, an area that has been called both the Golden Mile and the Napa Valley of the North. The company has also announced the closing of a share purchase agreement for 250 pristine acres in the Fraser Valley Regional District (“FVRD”) of British Columbia, one of the most productive and actively farmed areas in Canada (https://ibn.fm/j5u8R). This lush area features high-quality soil, a favorable climate, and an ample water supply.

“The addition of such a substantial package of land to our portfolio is a major step for PacRoots,” said PACR President and CEO Patrick Elliot. “We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre. This land has no zoning restrictions and is not situated within the Agricultural land reserve, which provides for infinite development possibilities.”

Pac Roots Cannabis Corp. began operations in 2012 with initial activities directed toward exploration and development of mineral properties in Canada. The company’s mission has evolved through time, and today, Pac Roots Cannabis Corp. is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top-quality products. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. Genetic variation and stability is the foundation that drives the decision-making for Pac Roots Cannabis Corp.’s business.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• MVES engaged services of Digital Talent Studio Inc., social media mogul Brian Breach of Sikey Corp. to promote The Movie Studio App
• The Movie Studio App leverages both advertiser-based and subscription models
• Social media models, influencers expected to promote app to hundreds of thousands of followers
• MVES’s two key verticals include open architecture for original content plus an over-the-top platform that pulls additional content through revenue sharing agreements

In a bold move to boost the promotion of The Movie Studio App, The Movie Studio Inc. (OTC: MVES), a vertically integrated motion picture production and distribution company, has engaged Digital Talent Studio Inc. and social media mogul Brian Breach of Sikey Corp. for services that include social media branding, influencer engagement and advertising on key social media platforms. Currently offered as a beta version in the Google Play Store and the Apple App Store, the app is expected to be replaced with the full version once the official launch takes place.

Designed to be a recurring revenue model, MVES’s unique video on demand (“VOD”) business goes beyond traditional feature film distribution pathways by offering innovative ways to distribute content and participate in the motion picture industry. Besides targeting relevant demographics through social media, high-profile influencers will be engaged in a revenue-sharing agreement that includes opportunities to audition in the company’s in-production “Moviesodes”.

“We are excited about engaging Digital Talent Studio Inc. and Sikey Corp. and believe they intrinsically understand the proposed app and our OTT platform architecture,” said MVES President and CEO Gordon Scott Venters (https://ibn.fm/CUKBD). “Upon completion of the app and subsequent marketing aligned with our brand, we are confident they can help us create a significant user subscription base.”

The Movie Studio app will employ a split-screen graphical interface that incorporates both advertiser video on demand (“AVOD”) and subscription-based video on demand (“SVOD”) components. Besides allowing users to watch ad-free for only $2.99/month, the SVOD component will also allow subscribers to participate in the “Be in Our Movies!” portion of the app, allowing them to audition for roles in upcoming films.

“Taking on The Movie Studio’s social media so they can reach their full potential and expand their online presence and the launch of their app could disrupt the entire independent movie industry, and I look forward to helping make that happen,” said Sikey President Brian Breach.

MVES’s two key verticals include an open architecture for the addition of motion picture content to its film library along with an over-the-top (“OTT”) platform that seeks to pull additional motion picture content into the app that leverages revenue share agreements with motion picture producers, distributors and content providers. Following the completion of the app, the initial marketing campaign will be put into play to target millennials and other demographics through high-profile influencers on top social networks like Facebook and Instagram.

“This partnership could take our models and social media influencers to the next level, launching their movie careers so they can be in films,” said Digital Talent Studio president Kevin Doyle.

“Similarly, we may provide the ultimate grassroots marketing campaign for The Movie Studio’s content delivery app and each of their films,” he continued. “Our influencers could announce their roles directly to their hundreds of thousands of followers, creating an instant demand for each movie and the SVOD component of the platform. Reciprocally, each movie can become an opportunity for our influencers to grow their follower bases and a chance to become viral stars.”

Formerly known as Destination Television, Inc., The Movie Studio Inc. acquires, develops, produces and distributes independent motion picture content for worldwide consumption in theatrical, video on demand, foreign sales, and on various media devices. With an aim to disrupt traditional media content delivery systems with its digital distribution model, MVES is well-positioned to become a unique brand within the VOD industry.

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• Mullen Technologies begins built-out of pilot facility, accepting orders for MX-05 SUV.
• Facility slated for April 2021 completion; first MX-05 SUVs rolling off production line by Q2 2022.
• In August, Net Element, Mullen Technologies announced execution of definitive agreement to merge.

The announcement by Mullen Technologies Inc. that it has begun to build out its pilot manufacturing facility and take pre-orders for its M05 fully electric SUV bodes well for Net Element (NASDAQ: NETE). Earlier this year, Net Element, a global financial technology and value-added solutions group, and Mullen Technologies announced a merger agreement—so good news for Mullen means good news for Net Element.

“We are excited to begin the build-out of our pilot facility and pre-sales of our MX-05 SUV in October,” said Mullen Technologies chairman and CEO David Michery. “We plan on completing the build-out by April 2021 and to begin assembly of certification prototypes by July 2021. These vehicles will be used for homologation, which is expected to take 16 months and be completed by May of 2022, at which time we expect to begin delivering the first vehicles to the public.”

On Oct. 1, Mullen began work to turn its Monrovia, California-based, high-voltage battery R&D center into a state-of-the-art pilot facility where its line of fully electric SUVs will be manufactured. Plans call for the facility to be completed by April 2021, with the first MX-05 SUVs rolling off the production line to be delivered to customers by second quarter 2022.

Mullen Technologies anticipates its remodeled manufacturing facility will produce up to 1,000 MX-05 EVs per year; the facility will also manufacture all other upcoming models, including the MX-07 and MX-03. The factory will be renovated to include general assembly and battery assembly capabilities; the structure will also house R&D and serve as a warehouse.

Also on Oct. 1, Mullen will begin accepting preorders for its MX-05 model; starting base price for the innovative vehicle starts at $55,000. In addition, the company is also taking preorders for its Dragonfly K50, a limited-production super sports car being imported under Independent Commercial Importers. Information about both vehicles, as well as how to reserve the EVs, can be found on www.MullenUSA.com or at any Mullen retail location.

In August, Net Element announced the execution of a definitive agreement to merge with privately held Mullen Technologies Inc., in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company. The completion of the merger is subject to shareholder and NASDAQ approval, as well as other conditions referenced in the merger agreement.

Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the United States and selected emerging markets.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology
• The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete
• Processa’s current development pipeline features multiple clinical drug candidates, given the recent acquisitions of three additional development-focused licensing agreement since June 2020
• In total, the company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration

Processa Pharmaceuticals (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (“FDA”) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.

Development Pipeline

The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:

1. Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
2. Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
3. Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.

Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.

PCS6422

On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.

An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.

“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.

PCS499

PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.

NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.

YH12852

On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (“GI”) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.

CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.

ATT-11T

On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.

The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.

PCS100

On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (“FSGS”), idiopathic pulmonary fibrosis (“IPF”) or Scleroderma, where there are still few therapeutic options.

Management Team

David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.

Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.

Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.

James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.

Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.

For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

• The partnership will help InsuraGuest’s coverage potentially reach more than 9,300 hospitality customers in the United States and Canada by the middle of 2021
• Hospitality Liability coverage allows covered properties to transfer certain liabilities, lowering claim ratio and risk profiles
• InsuraGuest’s product can also help properties generate revenue by keeping a percent of the nightly software fee

Innovative insurtech leader InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF) has sealed a premier preferred partnership with leading global insurance brokerage Hub International Limited (“HUB”), to provide InsuraGuest’s Hospitality Liability coverage to properties in Hub International’s portfolio. Signed via wholly owned subsidiary InsuraGuest, the deal will help HUB hotel clients significantly lower their insurance premiums, transfer small property and medical guest claims as well as generate additional revenue (https://ibn.fm/AYcJB).

The coverage will start with HUB clients in the United States, with the goal of expanding to Canadian hotel clients by the middle of 2021. According to InsuraGuest CEO and Chairman Douglas Anderson, the premier preferred partnership with HUB will allow the company to expand its product offering to more than 9,300 hospitality customers in the U.S. this year and into Canada in 2021.

The InsuraGuest Hospitality Liability coverage will allow HUB hotel clients to benefit from an extra layer of protection in case a guest experiences an accident, in-room property damage, accidental medical and death and dismemberment or theft while staying at an InsuraGuest-covered property.

Currently, InsuraGuest integrates with approximately 70 different property management systems through the proprietary API. The integrated use allows for the organization to transfer liabilities that fit specific criteria to the InsuraGuest carrier. The transfer of these liabilities to the InsuraGuest Hospitality Liability coverage enables hotel properties to lower their risk profile and claim ratio, thus decreasing General Liability premiums.

Most of a hotel client’s claims are from a small property or medical claim, which frequently gets applied to the General Liability coverages. With InsuraGuest, the risk is transferred from the hotel client through the small fee applied per night to the guest’s bill. InsuraGuest will then pay these small claims, keeping them off the hotel client’s General Liability policy.

The higher frequency of claims drives up the premiums paid by a hotel client for their General Liability policy coverage. With the transfer to InsuraGuest, the hotel client presents less risk for their general liability policy, lowering premiums.

In addition, hotels properties using InsuraGuest’s product will be able to generate additional revenue through the platform’s implementation. When a hotel offers the InsuraGuest Hospitality Liability coverages, an automatic charge is placed on their folio or bundled into their resort/amenity/urban fee upon check-in. The fee for coverage and software is $4.95 a night.

“Given the current state of the hospitality industry, it is nice to have a new and exciting tool such as InsuraGuest, which will help us lower a hotel’s overall liability costs through claims avoidance,” said Kevin Eggleston, the Managing Director of HUB’s Hospitality Specialty Practice. “InsuraGuest costs a hotel owner nothing. In fact, it actually generates new revenue while giving us the means to reduce General Liability premiums by improving guest loss ratios. By minimizing the frequency of a hotel’s claims, we are able to have better underwriting conversations with the marketplace.”

The hospitality industry is only one of the sectors InsuraGuest serves. The company’s goal is to disrupt the insurance landscape by utilizing its proprietary software platform to deliver digital insurance to multiple sectors. The company aims to transform the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold.

For more information, visit the company’s website at www.InsuraGuest.com.

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”)
• CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials
• One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin
• CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to prepare, through its sub-licensee partner WPD Pharmaceuticals, for a first-ever Phase I pediatric trial of Berubicin in Poland as well as continuing the development of the company’s second drug candidate, WP1244, which has shown tremendous promise in stopping cancer proliferation in preclinical studies comparing it to chemotherapy drug daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is building its technologically advanced strategy for demonstrating the potential brain tumor-fighting capabilities of its novel drug Berubicin, announcing recently an agreement with medical imaging company Image Analysis Group (“IAG”) to evaluate upcoming clinical phase II patient trial scansin real time.

IAG’s proprietary platform DYNAMIKA is an AI-driven technology developed to aid in the analysis of patient responses during pharmaceutical trial’s, and IAG has extensive experience in partnering with the biotech industry — oncology companies in particular — to provide a centralized reading of critical data, according to a news release about the partnership (https://ibn.fm/7OTsk).

CNS Pharmaceuticals is developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including the company’s lead drug candidate Berubicin, which aims to treat the aggressive brain cancer glioblastoma multiforme (“GBM”) (https://ibn.fm/4r5U3).

“This drug was designed specifically to penetrate the Blood-Brain Barrier and to treat cancers in the brain, which we all know are extremely difficult given that the brain is the most privileged organ in the body,” CNS CEO John Climaco told attendees at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as part of the company’s investment highlights presentation at the virtual conference Sept. 22 (https://ibn.fm/AzZv6).

During a 2006 Phase I clinical trial, Berubicin “appeared to demonstrate one durable, complete response against GBM,” Climaco said. The specified patient has remained cancer-free as of the last assessment on Feb. 20 of this year. Twenty-seven of the participating patients were able to be evaluated, and 44 percent of them experienced a clinically significant improvement in condition as a result of the trial.

Regarding IAG’s scientific and clinical imaging expertise in the field of GBM and the prowess of the company’s analytical API, Climaco stated, “IAG has an exemplary track record of partnering closely with companies in the biotech space to provide critical analysis of both efficacy and patient response, which we believe will be pivotal in advancing our Berubicin clinical trials.”

IAG CEO Dr. Olga Kubassova stated the platform will not only help CNS analyze Berubicin’s effectiveness and build scientific evidence of its performance but will also help the company efficiently reduce development costs, uncertainties about outcomes and timelines for the product’s advancement.

In addition to the Berubicin trials, CNS and its partner WPD Pharmaceuticals are preparing for a first-ever Phase I Berubicin trial for pediatric patients who have brain cancer. CNS is also developing a second drug candidate, WP1244, shown in preclinical studies to have a DNA-binding agent 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion.

“We are laser-focused as a company at this point on a critical unmet medical need, and that is the treatment of glioblastoma, which is the most aggressive, common and incurable form of brain cancer,” Climaco told conference attendees. “If you get glioblastoma, the devastating fact is you’re going to die from that disease. After decades without progress in the treatment of this terrible disease, we believe that Berubicin could potentially be a game-changer.”

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Pharmaceutical services innovator Trxade Group Inc. has gained investor attention as it has emerged as a responsive healthcare market force during the ongoing COVID-19 pandemic
• As the pandemic began to unfold earlier this year, Trxade Group saw revenues jump effectively to three times their previous Q1 level, largely as a result of personal protective equipment products
• The company’s core mission has been to help small, community-centered retail pharmacies compete with large national chains through prescription drug price transparency and AI-driven protocols that help pharmacies stay abreast of what’s available
• Trxade Group’s advances in delivering services ranging from consultation to drug shipping via virtual, remote-access technology has kept it abreast of developments as the effects of the pandemic have led to social-distancing limitations

The surprise manifestation of the novel COVID-19 coronavirus and its spread as a global pandemic this year has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services.

Telehealth services have been ideally situated for meeting remote access needs amid conditions in which the potential spread of a highly contagious virus has led medical policy makers to discourage close contact between people and gatherings in large numbers, especially indoors.

Five hundred healthcare industry executives surveyed by marketing agency Boston Digital recently reported the growing use of telehealth amid the pandemic has delivered largely positive results and the majority of the respondents said some of the changes in care protocols would undoubtedly remain in effect after the pandemic ends (https://ibn.fm/wTD8S).

Integrated pharmaceutical services innovator Trxade Group (NASDAQ: MEDS) has seen growing enthusiasm about its business profile during the course of the pandemic, largely because of revenue growth that has far exceeded expectations. The Q2 report showed a more-than-triple increase year-over-year to $6.6 million, practically tripling sequentially after Q1 this year as reported in a July earnings call (https://ibn.fm/KNVJs), which sent the stock soaring 35 percent immediately after the announcement, as noted in a Q3 research summary (https://ibn.fm/vBuoV).

The company’s artificial intelligence API is designed to streamline the transfer of information between healthcare industry businesses. Trxade’s model thereby helps smaller, independent pharmacies in particular to competitively serve patients in spite of the proliferation of large pharmaceutical chains.

But Trxade is also rolling out a first-of-its-kind bundled service that combines telehealth performance, a COVID-19 risk assessment tool and a personal protective equipment (PPE) purchasing tool. The bundled service will help businesses better deal with the medical needs of their internal corporate structures during the changing conditions as well as once the pandemic conditions have ended.

Trxade has been working to build its capital since uplisting to the Nasdaq exchange earlier this year (https://ibn.fm/C4wWa) and more recently gaining inclusion on this year’s Russell’s Microcap Index (https://ibn.fm/2120T). The company has also brought international investor relations specialists MZ Group on board to expand the company’s strategic investor relations program across all key markets.

The growing brand in the medical technology space has attracted nearly 11,700 independent pharmacies to its network — more than 50 percent penetration among the United States’ estimated 22,000 independent pharmacies.

“Our platform lets these independents know that they’re receiving a fair price from competing suppliers on fair payment terms and often with next day delivery,” Founder, Chairman and CEO Suren Ajjarapu said during the earnings conference call. “We believe this radical price transparency, economy of scale and competition amongst suppliers leads (to) up to 10% reduction in pharmacies’ total annual drug purchase costs, with a drug-level savings of up to 90% on certain pharmaceutical products.”

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• SGMD has filed updated Form 8K Current Report with SEC
• Filing includes information about issues related to company’s status, including planned expansion of BudCars cannabis-delivery service
• Sugarmade sees “major business opportunities out of both sites once operations begin”

Sugarmade (OTCQB: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, has released the publication of a Form 8K Current Report filing with the United States Securities and Exchange Commission (“SEC”) (https://ibn.fm/Ngrsg). The filing includes specific information about several issues related to the company’s performance and outlook, including planned expansion of the BudCars cannabis delivery service.

According to the filing (https://ibn.fm/wzDZ4), the highly successful Sacramento, California-based BudCars, which has reported record sales for the past several months (https://ibn.fm/YWib6), has plans to open two hubs in Los Angeles in the coming months.

“One of the Los Angeles sites is behind schedule, and the other is well ahead of schedule,” the filing reported. “We still expect both to become operational as soon as final issues are resolved.” Sugarmade, which has a 40% interest in BudCars with an option to purchase a controlling interest, noted that last-minute regulatory issues were causing some delays in opening of the first location.

“The first of these expansions was expected to go online during July, and significant progress toward opening has taken place,” the filing noted. “Unfortunately . . . we are still working to get the security plan approved by local authorities, and we have a few minor issues relative to facilities build-out concerning the Americans with Disabilities Act (‘ADA’). As soon as these final issues are cleared, we plan to begin operations.”

“On the positive side, we are ahead of schedule at the other Los Angeles site,” the report continued. “We are happy to report the turn-up of this second site could occur sooner than was expected. Of course, we see major business opportunities out of both sites once operations begin. We will be sure to keep everyone updated. We are working hard daily on both sites.”

The filing noted that the cannabis delivery trend is growing substantially. “This is resulting in increases in the number of new customers and in the average sale size on a per-delivery customer basis,” the filing concluded. “We see cannabis delivery continuing to accelerate. Certainly, the Los Angeles market is especially robust relative to delivery services.”

BudCars is a retail business that offers same-day delivery of top-quality cannabis. Customers choose from a variety of products, including edibles, flower, pre-rolls, vapes, tinctures and concentrate across dozens of premium brands. Once consumers complete their purchases online, they receive their order the same day via BudCars Cannabis Delivery Service.

Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes CarryOutsupplies.com and SugarRush(TM).

or more information, visit the company’s website at www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR